Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10 9월 2024 - 5:00AM
Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its
commitment to non-opioid pain management and regenerative health
solutions, today announced the granting of inducement awards on
September 4, 2024 to 17 new employees under Pacira’s Amended and
Restated 2014 Inducement Plan as a material inducement to each
employee's entry into employment with the company. In accordance
with Nasdaq Listing Rule 5635(c)(4), the awards were approved by
the Compensation Committee of the Board of Directors.
Two employees received stock options to purchase an aggregate of
5,000 shares of Pacira common stock and 17 employees received
restricted stock units for an aggregate of 30,000 shares of Pacira
common stock.
The stock options have a 10-year term and a four-year vesting
schedule with 25 percent of the underlying shares vesting on the
first anniversary of the recipient’s first day of employment and in
successive equal quarterly installments over the 36 months
thereafter. The stock options have an exercise price of $15.14 per
share, the closing trading price of Pacira common stock on the
Nasdaq Global Select Market on the date of grant. Each restricted
stock unit represents the contingent right to receive one share of
Pacira common stock and the restricted stock unit awards vest
annually in four equal installments beginning on the first
anniversary of September 1, 2024.
Vesting of the equity awards is subject to the employee’s
continued employment with Pacira. Each equity award is also subject
to the terms and conditions of an award agreement.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to
providing non-opioid pain management options to as many patients as
possible to redefine the role of opioids as rescue therapy only.
Pacira has three commercial-stage non-opioid treatments: EXPAREL®
(bupivacaine liposome injectable suspension), a long-acting local
analgesic currently approved for infiltration, fascial plane block,
and as an interscalene brachial plexus nerve block for postsurgical
pain management; ZILRETTA® (triamcinolone acetonide
extended-release injectable suspension), an extended-release,
intra-articular injection indicated for the management of
osteoarthritis knee pain; and ioveraº®, a novel, handheld device
for delivering immediate, long-acting, drug-free pain control using
precise, controlled doses of cold temperature to a targeted nerve.
To learn more about Pacira, including the corporate mission to
reduce overreliance on opioids, visit www.pacira.com.
Forward-Looking Statements
Any statements in this press release about Pacira’s future
expectations, plans, trends, outlook, projections and prospects,
and other statements containing the words “anticipate,” “believe,”
“can,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“project,” “should,” “will,” “would,” and similar expressions,
constitute forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and the Private Securities Litigation Reform Act
of 1995, including, without limitation, statements related to our
intellectual property, our growth and future operating results and
trends, our strategy, plans, objectives, expectations (financial or
otherwise) and intentions, future financial results and growth
potential, including our plans with respect to the repayment of our
indebtedness, anticipated product portfolio, development programs,
patent terms, development of products, strategic alliances, plans
with respect to the Non-Opioids Prevent Addiction in the Nation
(“NOPAIN”) Act and other statements that are not historical facts.
For this purpose, any statement that is not a statement of
historical fact should be considered a forward-looking statement.
We cannot assure you that our estimates, assumptions and
expectations will prove to have been correct. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including
risks relating to, among others: the integration of our new chief
executive officer; risks associated with acquisitions, such as the
risk that the acquired businesses will not be integrated
successfully, that such integration may be more difficult,
time-consuming or costly than expected or that the expected
benefits of the transaction will not occur; our manufacturing and
supply chain, global and U.S. economic conditions (including
inflation and rising interest rates), and our business, including
our revenues, financial condition, cash flow and results of
operations; the success of our sales and manufacturing efforts in
support of the commercialization of EXPAREL, ZILRETTA and iovera°;
the rate and degree of market acceptance of EXPAREL, ZILRETTA and
iovera°; the size and growth of the potential markets for EXPAREL,
ZILRETTA and iovera° and our ability to serve those markets; our
plans to expand the use of EXPAREL, ZILRETTA and iovera° to
additional indications and opportunities, and the timing and
success of any related clinical trials for EXPAREL, ZILRETTA and
iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°;
the related timing and success of U.S. Food and Drug Administration
supplemental New Drug Applications and premarket notification
510(k)s; the related timing and success of European Medicines
Agency Marketing Authorization Applications; our plans to evaluate,
develop and pursue additional product candidates utilizing our
proprietary multivesicular liposome (“pMVL”) drug delivery
technology; the approval of the commercialization of our products
in other jurisdictions; clinical trials in support of an existing
or potential pMVL-based product; our commercialization and
marketing capabilities; our ability to successfully complete
capital projects; the outcome of any litigation; the ability to
successfully integrate any future acquisitions into our existing
business; the recoverability of our deferred tax assets;
assumptions associated with contingent consideration payments; the
anticipated funding or benefits of our share repurchase program;
and factors discussed in the “Risk Factors” of our most recent
Annual Report on Form 10-K and in other filings that we
periodically make with the Securities and Exchange Commission (the
“SEC”). In addition, the forward-looking statements included in
this press release represent our views as of the date of this press
release. Important factors could cause actual results to differ
materially from those indicated or implied by forward-looking
statements, and as such we anticipate that subsequent events and
developments will cause our views to change. Except as required by
applicable law, we undertake no intention or obligation to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise, and readers should not
rely on these forward-looking statements as representing our views
as of any date subsequent to the date of this press release.
Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com
Media Contact:
Sara Marino, (973) 370-5430
sara.marino@pacira.com
Pacira BioSciences (NASDAQ:PCRX)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Pacira BioSciences (NASDAQ:PCRX)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024